💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadUnlock them all

BRIEF-Valeant Pharmaceuticals announces expanded discounts for Nitropress and Isuprel

Published 2016-05-16, 08:37 a/m
© Reuters.  BRIEF-Valeant Pharmaceuticals announces expanded discounts for Nitropress and Isuprel
BHC
-

May 16 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX)
VRX.TO
* Valeant Pharmaceuticals announces expanded discounts for
Nitropress and Isuprel
* Under enhanced program, all hospitals are eligible for a
rebate of at least 10%
* All hospitals are eligible for a rebate of at least 10%,
with rebates totaling 20%, 30% or 40% based on volume bought
during a calendar quarter for hospitals that purchase large
volumes of relevant drug
* Hospitals will receive these discounts primarily through
their group purchasing organization
* Hospitals that don't buy drugs through a gpo can access
program by contacting Valeant customer service
* Rebate program is effective immediately, with hospitals
receiving rebates after end of quarter in which purchases were
made
* Atient access and pricing committee also confirmed that
there would be no further price increases for these products or
reductions to discount levels in rebate program

Source text for Eikon: ID:nCNWd5HyWa
Further company coverage: VRX.TO

(Bengaluru Newsroom: +1 646 223 8780)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.